F&P Healthcare's product pipeline expected to boost sales past $1b
Chief executive speaks on litigation costs, possible US tax hikes and product pipeline.
Fisher & Paykel Healthcare’s [NZX:FPH] packed product pipeline will boost the medical device maker’s sales past the $1 billion mark, its management predicts.
The Auckland-based company reported a record profit today, up 18% to $169 million in the 12 months ended March 31.
Operating revenue
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Calida Smylie
Mon, 22 May 2017
Mon, 22 May 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
F&P Healthcare's product pipeline expected to boost sales past $1b
67150